



Understanding Diabetes

A Biochemical Perspective



RICHARD F. DODS

UNDERSTANDING DIABETES



This image depicts a watercolor representation (by the author) of a single pancreatic islet of Langerhans as seen through a light microscope. The nuclei are visualized through staining as blue; the glucagon produced by the α -cells is stained as red-orange and the insulin produced by the β -cells as green.

UNDERSTANDING DIABETES

A Biochemical Perspective

RICHARD F. DODS

 **WILEY**

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2013 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.
Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Dods, Richard F., 1938-

Understanding diabetes : a biochemical perspective / by Richard F. Dods.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-35009-6 (cloth)

I. Title.

[DNLM: 1. Diabetes Mellitus. 2. Glucose--metabolism. WK 810]

616.4'62--dc23

2012040252

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

CONTENTS

PREFACE	xvii
1 DIABETES MELLITUS: A PANDEMIC IN THE MAKING	1
Diabetes Prevalence and Cost in the United States / 2	
A Dire Prediction Based on Alarming Data / 2	
The Increase of Diabetes in Youths / 4	
The Cost / 6	
Diabetes Prevalence and Cost Worldwide / 7	
A Worldwide Epidemic / 7	
Numbers of Cases of Diabetes / 7	
Cost / 7	
Obesity and Overweight; Another Epidemic in the United States / 9	
A Parallel Pandemic / 9	
Definitions of Overweight and Obesity / 9	
Overweight and Obesity among Adults in the United States / 9	
Obesity and Overweight among Children and Adolescents in the United States / 12	
Overweight and Obesity Worldwide / 14	
Overweight and Obesity Globally in Adults / 14	
Overweight and Obesity in Children / 16	

The Relationship Between Obesity and Diabetes / 16
Projects and Questions / 18
Glossary / 18
References / 19

2 AN EARLY HISTORY OF DIABETES MELLITUS

23

Translation / 24
More simply stated / 24
The Ebers Papyrus / 24
Neandertals / 25
Hippocrates, Aretaeus, and Demetrius / 25
Galen / 26
Sushruta / 27
Ibn Sina (Avicenna) / 28
The Yellow Emperor / 29
Japanese Medicine / 29
Paracelsus (Philippus Aureolus Theophrastus Bombastus von Hohenheim) / 30
Thomas Willis / 31
Johann Conrad Brunner / 31
Matthew Dobson / 31
John Rollo and William Cruickshane / 32
Thomas Cawley / 33
Michel Eugene Chevreul / 34
Claude Bernard / 34
Paul Langerhans (Edouard Laguesse and Eugene L. Opie) / 35
Oscar Minkowski and Josef von Mering / 36
Advances in Sugar (Glucose) Determinations / 37
 Earliest Approaches—Taste and Fermentation / 37
 Evaporation of Urine to Yield Sugar Crystals / 38
 Moore's Test / 38
 Trommer's Test / 39
 Barreswil and Fehling's Solutions / 39
 Frederick Pavy / 40
 Benedict's Solution / 40
 Folin–Wu Determination of Blood Glucose / 41
Banting, Best, and MacLeod / 43
 Leonard Thompson / 44

John Jacob Abel / 45
Frederick Sanger / 45
Pedro Cuatrecasas / 48
Questions and Crossword Puzzle / 50
References / 52

3 A PRIMER: GLUCOSE METABOLISM

55

Prolog / 55
The Carbohydrates and their Function / 56
Digestion and Absorption of Carbohydrates / 57
Salivary and Pancreatic Amylase / 57
Disaccharidases / 58
Absorption / 59
Overview of Glucose Metabolism / 60
Adenosine 5'-Triphosphate (ATP) / 61
Glucose Metabolism / 63
Glucose Transport into Cells / 63
Phosphorylation of Glucose / 64
Introduction to Glycogen Synthesis and Hydrolysis / 65
Beautiful Concepts / 65
Glycogen Synthesis / 66
Uridine Bisphosphate Glucose (UBP-Glucose) / 67
Glycogen Synthase / 67
Branching Enzyme / 69
Glycogenolysis / 69
Debranching Enzyme / 70
Glycogen Phosphorylase / 71
Phosphoglucomutase / 71
Glucose 6-Phosphatase / 72
$\alpha(1 \rightarrow 4)$ -Glucosidase / 72
Synchronization of Glycogenesis and Glycogenolysis (A Beautiful Pathway) / 72
Dephosphorylation / 73
Effectors / 73
Glycolysis (Glycolytic Pathway) / 75
Phosphoglucose Isomerase / 75
Phosphofructokinase / 76
Aldolase / 76

Triose Phosphate Isomerase / 76
Glyceraldehyde 3-Phosphate Dehydrogenase / 77
Erythrocyte Bisphosphoglyceromutase and Bisphosphoglycerate Phosphatase / 77
3-Phosphoglycerate Kinase / 78
Phosphoglyceromutase / 78
Enolase / 78
Pyruvate Kinase / 78
Lactate Dehydrogenase / 79
Tricarboxylic Acid Cycle / 80
The Coenzymes: Nicotinamide Adenine Dinucleotide (NAD ⁺) and Flavin Adenine Dinucleotide (FADH) / 81
Steps in the Tricarboxylic Acid Cycle / 83
Pyruvate Dehydrogenase; Acetyl CoA / 83
Pyruvate Decarboxylase / 84
Dihydrolipoyl Transacetylase / 85
Dihydrolipoyl Dehydrogenase / 86
Citrate Synthase / 86
Aconitase / 86
Isocitrate Dehydrogenase / 87
α -Ketoglutarate Dehydrogenase / 87
Succinate Dehydrogenase / 88
Fumarase / 89
L-Malate Dehydrogenase / 89
Pyruvate Carboxylase / 89
Glycolysis / 90
Tricarboxylic Acid Cycle / 90
Sum Total of Glycolysis and Tricarboxylic Acid Cycle / 90
Summary / 90
The Electron Transport System and Oxidative Phosphorylation / 91
Steps in the Electron Transport System / 92
Oxidative Phosphorylation (ATP Synthase) / 95
Shuttles / 97
Glycerol 3-Phosphate Shuttle / 97
Malate–Aspartate Shuttle / 97
Moles ATP Produced by Oxidative Phosphorylation from 1 mol of Glucose / 97

The Phosphogluconate Oxidative Cycle / 98	
Steps in The Phosphogluconate Oxidative Cycle / 99	
Glucose 6-Phosphate Dehydrogenase; Lactonase / 99	
Transaldolase / 101	
Transketolase / 101	
The Fate of Glyceraldehyde 3-phosphate / 101	
Uronic Acid Pathway / 103	
Hexosamine Biosynthesis Pathway / 104	
The Steps of Gluconeogenesis / 105	
Conclusions / 108	
Questions / 108	
Glossary / 109	

4 REGULATION OF GLUCOSE METABOLISM

113

Insulin / 114	
Structure / 114	
Transport and Secretion of Insulin / 114	
Insulin Signaling Pathways / 118	
Akt Pathway / 119	
GLUT4 Translocation / 120	
Insulin-Stimulated Glycogenesis / 121	
Insulin-Stimulated Inhibition of Gluconeogenesis / 123	
Insulin-Stimulated Protein Synthesis / 123	
Insulin-Stimulated Lipogenesis (Fatty Acid Synthesis) / 124	
Insulin-Inhibited Lipolysis (Fatty Acid Hydrolysis) / 124	
Scaffold Proteins / 125	
The Incretin Hormones (Incretins) / 128	
Amylin / 131	
Other Hormones / 133	
Glucagon / 133	
Epinephrine / 135	
Somatotropin (Growth Hormone) / 137	
Somatostatin (SST) / 139	
Cortisol / 140	
Adrenocorticotropin / 142	
Thyroid Hormones / 143	
Insulin-Like Growth Factor (IGF) / 146	

Fibroblast Growth Factor 19 / 146
Adenosine 5'-Monophosphate-Activated Protein Kinase / 147
Glossary / 149
References / 150

5 GLUCOSE METABOLISM GONE WRONG 153

Pancreatic β -Cell Mass / 156
Glucose Transport and Hexokinase / 158
Glycogen Synthesis and Breakdown / 160
Glycogen Cycling / 161
Gluconeogenesis and Glycogenolysis / 164
Glycolysis, Glucose Oxidation, and Pyruvate Dehydrogenase / 166
Mitochondrial Defects / 169
 Tricarboxylic Acid Pathway and Oxidative Phosphorylation / 169
Hexosamine Biosynthesis Pathway / 174
Techniques Used in the Investigations / 175
 Hyperinsulinemic-Euglycemic Clamp / 175
 Vastus Lateralis Muscle Biopsy / 176
Glossary / 176
References / 177

6 CLASSIFICATION SYSTEM FOR DIABETES MELLITUS 183

T1D / 184
Latent Autoimmune Diabetes (LADA) or Type 1.5 / 184
T2D / 187
Hybrid / 187
Idiopathic Diabetes (T1b) / 187
Secondary / 187
Genetic Defects of β -islet Function / 188
 Mody / 188
Other Genetic Defects of the β -cell / 189
 Genetic Defects in Insulin Action / 189
Diseases of the Exocrine Pancreas / 190
Endocrinopathies / 190
Drug or Chemically Caused Diabetes / 190
Infections / 191

Uncommon Forms of Immune-Mediated Diseases /	191
Other Genetic Syndromes Sometimes Associated With Diabetes /	192
Prediabetes /	192
Gestational Diabetes Mellitus (GDM) /	193
Statistical Risk Classes /	194
Metabolic Syndrome /	195
Glossary /	197
References /	198

7 DIAGNOSIS OF DIABETES MELLITUS

201

PART 1: Establishing a Normal Range /	201
The Concept of Normal and Abnormal Populations /	201
The Probability Factor in Diagnosing Disease /	203
Probability of Disease and Prevalence /	203
The Normal Range /	204
Assay Sensitivity and Specificity /	205
Relationships Among Sensitivity, Specificity, Prevalence, Predictability, and Normal Range /	207
Exercise /	208
How Does One Choose a Normal Range? /	209
Truthfulness (Efficiency) /	209
Non-gaussian Distribution /	210
The Effect of Reproducibility on Sensitivity and Specificity /	210
Severity of Disease and Assay Results /	211
Parallel and Series Multiparameter Testing /	212
Exercise /	213
Example /	215
Example /	216
References /	216
PART 2: Modern Techniques for the Quantitation of Glucose /	216
Methods of Historical Interest /	216
Modern-day Methods of Measuring Glucose /	218
Glucose Oxidase/Peroxidase/Chromogen /	218
Hexokinase/NADP /	220
Exercise /	221
Glycated Hemoglobin /	221
Specimen Collection /	223

Exercise / 225
The Gold Standard / 225
Instrumentation / 226
References / 229
PART 3: Symptoms and Tools for the Diagnosis of Diabetes Mellitus / 230
The Symptoms of Diabetes Mellitus / 231
Individuals Who Should be Tested for Diabetes / 231
Tools for the Diagnosis of Diabetes / 233
 Urinary Glucose / 233
 Fasting Blood Glucose / 233
 Oral Glucose Tolerance Test / 234
 HbA_{1c} / 235
Cut Points for the Diagnosis of Diabetes / 237
Diagnosis of Diabetes Using FBG, 2-h PG, or HbA_{1c} / 239
Diagnosis of Gestational Diabetes Mellitus / 239
Autoimmune Antibodies as Predictors for T1D And LADA / 241
Glossary / 245
References / 246

8 COMPLICATIONS OF DIABETES MELLITUS AND THEIR PATHOPHYSIOLOGY

249

The Complications of Diabetes Mellitus / 249
 Retinopathy and Other Eye Complications / 249
 Neuropathy and Related Conditions / 252
 Nephropathy, Diabetic Kidney Disease (DKD), and End-Stage Renal Disease / 254
 Cardiovascular Disease (CVD), Hypertension, Coronary Heart Disease or Coronary Artery Disease (CHD), Cerebrovascular Accident (CVA), Pathophysiology of CVD: Endothelial Dysfunction / 258
 The Pathophysiology of CVD: Endothelium Dysfunction / 260
 Diabetic Ketoacidosis (DKA) / 265
 Hyperglycemic Hyperosmolar Non-Ketotic Syndrome / 266
 Hypoglycemia / 266
 Infections / 267

Alzheimer's Disease or Alzheimer Disease (AD) /	269
Diabetes and Cancer /	270
Pathophysiology of Diabetic Complications /	272
Glycation /	272
Sorbitol Accumulation /	275
Reactive Oxygen Species (ROS) in Diabetes /	275
Glossary /	278
References /	278

9 HEREDITARY TRANSMISSION OF DIABETES MELLITUS

283

Inheritance of T1D in Monozygotic and Dizygotic Twins /	284
Pairwise and Probandwise Concordance in T1D /	284
Pairwise and Probandwise Concordance in T2D /	286
Diabetes in Offspring of One or Two Diabetic Conjugal (Biological) Parents /	288
Diabetes in Siblings of Diabetics /	289
Summary /	289
The Genetic Component of Diabetes Mellitus /	290
The Major Histocompatibility Complex Proteins or Human Lymphocyte Antigens and Disease /	290
Online Mendelian Inheritance in Man /	293
HLA Nomenclature /	294
HLAs and Diabetes Mellitus /	295
T1D and Class II Genes /	295
T1D and Class I Genes /	297
Non-HLA T1D Promoting Alleles /	298
Genetics of T2D /	298
T1D and Environment /	306
Enteroviruses (Coxsackie B Virus) /	308
Rubella Virus (German Measles) /	309
Mumps Virus /	310
Cytomegalovirus /	310
Retrovirus /	310
Reovirus and Rotavirus /	310
Epstein–Barr Virus /	311
Viruses that Need More Evidence for the Assumption that They Promote T1D in Humans /	311

- Viruses That Produce T1D in Animals but so Far no Evidence in Humans / 311
- Other Environmental Factors / 312
 - Early Exposure to Cow's Milk as Opposed to Breast Milk / 312
 - Vitamin D / 313
- Summary / 314
- Genes and Obesity / 314
 - The FTO Gene / 315
 - The KLF14 Gene / 316
- Projects / 317
- Glossary / 317
- References / 318

10 TREATMENT

323

- PART 1: Medicinal Treatment / 323
- Insulin (Early Treatment) / 323
- It is Not Your Father's Insulin Any More
- Modern-Day Human Insulin / 326
 - Genetically Engineered Insulin Derivatives / 327
 - Other Modes of Delivering Insulin: Tablets or Capsules, Inhalable Insulin and Nasal Spray Insulin / 330
 - Closed-Loop Insulin Delivery (Artificial Pancreas) / 330
 - Islet Transplantation and Stem Cell Therapy / 331
- Antidiabetic Oral Drugs / 332
 - Sulfonylureas / 332
 - Biguanides / 333
 - Thiazolidinediones / 335
- Incretin-Based Inhibitors / 335
 - Exenatide / 337
 - Liraglutide / 337
 - Albiglutide and Taspoglutide (Long-Acting Release) / 337
 - Sitagliptin, Vildagliptin, and Saxagliptin / 337
- Amylin Derivatives (Pramlintide) / 339
- Glucokinase Activators (GKA): Potential Anti Diabetic Compounds / 340
- α -Glucosidase Inhibitors / 341
- Other New Strategies that are in the Clinical Trials Phase / 342
 - SGLT2 Inhibitors / 342

11 β -Hydroxysteroid Dehydrogenase Type 1 Inhibitors / 342	
References / 343	
PART 2: Prevention, Delay and Management / 345	
Prevention and Delay / 345	
Exercise / 346	
Evidence / 347	
Diet / 349	
Biochemistry of the Beneficial Effects of Exercise / 349	
Gastric Bypass Surgery (A Cure for T2D?) / 350	
Project / 352	
Glossary / 352	
References / 352	
POSTSCRIPT	355
The Future / 355	
APPENDIX A	357
General Assembly / 358	
The White House / 359	
APPENDIX B	361
Problems / 361	
INDEX	377

PREFACE

In this book we commence a fascinating journey that will describe attempts to conquer a disease, really a scourge, which began as far back in history as earliest man, and continues today. Unfortunately we do not presently have a cure, but I feel we are on the brink of one.

This book is written for the individual who wants to learn about the underlying biochemistry/physiology of diabetes mellitus, its history, its detection, its complications, and its treatment.

Alan Alda in an editorial published in *Science*,¹ states “Scientists urgently need to speak with clarity to funders, policy-makers, students, the general public, and even other scientists. . . . clarity in communicating science is at the very heart of science itself”. This book was written with this statement in mind.

Although not absolutely required, a basic knowledge of biochemistry/physiology will help the reader understand certain concepts presented in this book. However, in order to make technical language, objectives, and concepts more easily understood this book includes for each chapter a *Glossary*, *Summary*, and *Problems*. The *Glossary* defines key terms used in the chapter. The *Summary* highlights the essential ideas presented in each section of the chapter. *Problems* for each chapter located in Appendix B present the principal goals of the chapter in the form of questions for the reader. Technical terminology is presented in simple, easily understandable terms with the aid of *Footnotes*.

¹Alan Alda, actor, writer, and founding board member of the Center for Communicating Science, State University of New York at Stony Brook from The flame challenge. Editorial. *Science* 2012;335:1019.

MY GOALS IN WRITING THIS BOOK

My goals in writing this book were

- To give the reader a view of diabetes mellitus, a disease that is in epidemic proportions worldwide, by identifying its biochemical basis, classification types, causes, diagnosis and monitoring, complications, and present and future treatment modalities.
- To provide students enrolled in a university-level biochemistry course the materials to understand glucose metabolism and what occurs when the metabolism goes astray.
- To provide incentive for further research on this disease by presenting what we presently know about diabetes.
- To provide a fundamental understanding of the tests used for the diagnosis and monitoring of diabetes—assays that Medical Technologists and Clinical Chemists perform every day.
- To give diabetes counselors and educators a text and reference book that they can use with confidence.
- To provide to medical students and physicians an understanding of the underlying basis for the disease that they treat.
- To provide policy-makers with an understanding and appreciation of the disease that promotes the support of public funds for the research, treatment, and eventual cure of the disease.
- For persons afflicted with diabetes an appreciation of how science is researching this disease and the many breakthroughs that have recently occurred in comprehending the causes, complications, diagnosis, and treatment of this disease.

After reading this book I hope you will agree that these goals have been achieved.

CONTENT

This book is intended to acquaint the reader with diabetes mellitus, a disease that is becoming pandemic.

In Chapter 1, “Diabetes Mellitus: A Pandemic in the Making”, diabetes mellitus is introduced as a disease that is attaining epidemic proportions in the United States and across the world. Parallel to the outbreak of diabetes there is another developing pandemic: overweight and obesity. The connection between these two developing pandemics is discussed in this chapter and will be further elaborated on in Chapter 6.

In Chapter 2, “A Historical View of Diabetes Mellitus”, the history of the disease is presented from the caveman to its recognition in ancient Greek medicine and the early days of the Roman Empire to Banting and Best’s Nobel Prize winning discovery of insulin to Sanger’s determination of the structure of insulin to Cuatrecasas’s purification of the receptor site for insulin.

Chapter 3, “A Primer: Glucose Metabolism”, contains the pathways for the metabolism of glucose. It includes the principal pathways by which glucose is metabolized: glycogenesis and glycogenolysis, glycolysis, the tricarboxylic acid pathway, electron transport system and oxidative phosphorylation, phosphogluconate oxidative cycle, uronic acid cycle, hexosamine biosynthesis pathway, and gluconeogenesis are described. Included in this chapter are “beautiful concepts” as seen through the elegance of many of these metabolic pathways. The notion of “beautiful pathways” is elaborated on in the Prolog to Chapter 3.

Chapter 4, “Regulation of Glucose Metabolism” relates the mechanisms that permit glucose to enter the cell from the blood. Included in this chapter are descriptions of insulin action, its manufacture in β -cells, the insulin signaling pathway, incretins, and other hormones that regulate insulin production, and the actions of AMP-activated protein kinase.

In Chapter 5, “Glucose Metabolism Gone Wrong”, the altered metabolism of glucose in diabetics is presented.

Chapter 6, “Classification System for Diabetes Mellitus”, deals with the classification scheme for diabetes that has been developed over the years. Described in this chapter are type 1, type 2, impaired glucose tolerance, impaired fasting glucose, gestational diabetes, statistical risk class, potential abnormality of glucose tolerance, and secondary causes of diabetes mellitus.

Chapter 7, “Diagnosis of Diabetes Mellitus”, is divided into three parts—Part 1 deals with the approach to establishing the normal range; Part 2 the modern laboratory tests for glucose; and Part 3 symptoms, diagnostic tests, and criteria used to identify diabetes.

Chapter 8, “Complications of Diabetes Mellitus and Their Pathophysiology”, describes the complications of diabetes retinopathy, angiopathy, nephropathy, infection, hyperlipidemia, atherosclerosis, ketoacidosis, lactic acidosis, hyperglycemic hyperosmolar nonketotic coma, and hypoglycemia. Their pathophysiology and prevalence will also be discussed.

In Chapter 9, “Hereditary Transmission of Diabetes Mellitus”, the hereditary factors that are involved in the susceptibility and resistance to diabetes are discussed. The histocompatibility antigens (HLA) and their association with diabetes are described.

Chapter 10, “Treatment”, goes into a discussion of advancements in the treatment of the disease. Some of what is discussed in this chapter represents ongoing research into the disease. Also treated in this chapter are measures to delay and prevent the occurrence of diabetes.

Postscript “The Future”.

LEARNING AIDS

- Throughout the chapters, Problems, Summary, and Key Terms are listed. These aids are to guide readers as they navigate through the chapters. They permit the reader a shortcut that may be used to scan chapters that are not totally relevant to the reader's interest.
- The goals of each chapter are contained in the Problems located in Appendix B. In addition, summaries are included throughout each chapter.
- Key terms (including medical terms) are explained at each point as they are introduced in the chapter. A glossary of key terms is also included at the end of each chapter.
- Each chapter has a preamble as to its importance in understanding diabetes mellitus. In addition each chapter has a summary.
- Each chapter has numbers within parenthesis relating to references, which are listed in the reference section at the end of the chapter. Included are the URLs for many of the citations. Also the Digital Object Identifier (DOI[®]) for many articles is included. DOI has been around since 2000. DOIs identify electronic objects such as journal articles, books, and scientific data sets in a particular location on the Internet. The system is managed by the International DOI Foundation (IDF), a consortium of commercial and non-commercial partners. A DOI name consists of a prefix and a suffix, for example, 10.1089/jwh.2010.2029; the prefix is 10.1089 and the suffix is jwh.2010.2029. One way to use this system is to go to the URL of the IDF, which is <http://www.doi.org/> and insert the DOI you are in search of in the place provided and violá the document pops up. The other approach is to use the URL, <http://dx.doi.org/> followed by the DOI name; for example: <http://dx.doi.org/10.1089/jwh.2010.2029>.


TECHNICAL TERMS

Technical terms are translated into simple language in this book. When I read an article or book, I find myself spending a considerable amount of time trying to learn the meaning of technical terms with which I am not familiar. I often turn to reference books and textbooks to learn the meaning of the term. In this book I think I have remedied this by having footnotes and a glossary defining any technical terms that you may come across in the text.

MY BACKGROUND AND INTEREST IN DIABETES MELLITUS

As you can see from the image shown below I had an interest in diabetes mellitus early during my education. The image is from a science notebook while I was in high school, Lafayette High School in Brooklyn, New York, to be specific.

Although Lafayette no longer exists it still remains alive in my heart as to where I started my career in science.



I earned a B.S. in science at Brooklyn College, an M.S. in organic chemistry at New York University and a PhD in biochemistry at the University of Connecticut. I was a post-doctoral fellow in cancer research at Sloan Kettering Institute for Cancer Research before joining New York University Medical School as a research associate. It was at the medical center that I first became acquainted with diabetes mellitus and published papers on the biochemistry of the beta cell. My

paper² was one of the early publications characterizing beta cell protein kinase and protein phosphatase.

I studied clinical biochemistry as an NIH fellow under the esteemed Dr Samuel Natelson at Michael Reese Medical Center in Chicago. As Director of Clinical Chemistry at Louis A. Weiss Memorial Hospital in Chicago (a position which included an Adjunct Assistant Professorship with the University of Illinois Medical School), I published papers on the use of HbA_{1c} as a test for monitoring diabetes mellitus. This article³ was one of the earliest suggesting HbA_{1c} as a tool for the diagnosis of diabetes. While at Weiss, I earned a Diplomate in Clinical Biochemistry from the American Board of Clinical Chemistry.

I wrote the chapter on Diabetes Mellitus for four of the five editions (the exception being the first edition) of *Clinical Chemistry: theory, analysis, and correlation*, edited by Lawrence Kaplan and Amadeo J. Pesce. I have also authored two audiocassette courses for the American Chemical Society entitled “*Clinical Chemistry*” and “*Pathophysiology for Chemistry*”. I established a company, Clinical Laboratory Consultants, which advised hospital and commercial laboratories in the implementation and interpretation of assays and the use of instruments for the diagnosis and monitoring of disease. Lastly I taught organic chemistry and biochemistry for 17 years at the Illinois Mathematics and Science Academy (IMSA), a world renowned secondary school funded by the Board of Higher Education of the State of Illinois. While at IMSA I published several papers on problem-based learning and its utilization in content-rich courses.^{4,5}

DEDICATIONS

This book is dedicated to

My wife who supported and encouraged me throughout the writing of this book and helped me when I grappled with sentences that were so convoluted that they made little or no sense.

My cousin, Stanley Menson, who helped initiate my interest in science with his turtle tank. He was a biology teacher for the deaf and succumbed from the complications of type 2 diabetes too soon.

My grandchildren, Rachel and Shannon, who I hope will follow in my footsteps into the wonderful world of science.

My son, Steven, who has already followed me into science as an electrical engineer.

²Dods RF, Burdowski A. Adenosine 3′5′-cyclic monophosphate dependent protein kinase and phosphoprotein phosphatase activities in rat islets of Langerhans. *Biochem Biophys Res Commun* 1973;51:421.

³Dods RF, Bolmey C. Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus. *Clin Chem* 1979;25:764.

⁴Dods RF. A problem-based learning design for teaching biochemistry. *J Chem Educ* 1996;73:225.

⁵Dods RF. An action research study of the effectiveness of problem-based learning in promoting the acquisition and retention of knowledge. *J Educ Gifted* 1997;20:423.

ACKNOWLEDGMENTS

I sincerely appreciate the contributions of those who initially reviewed portions of the text and found them worthy enough of being incorporated into a book. They were Edward Hobart, M.D., Lawrence Kaplan, Ph.D., and Amadeo Pesce, Ph.D. I thank Professor Anne Cooke who contributed the remarkable cover micrograph of T-cells attacking beta islets. I greatly appreciate the information supplied to me by Thomas F. Mich, Ph.D, retired Vice-President of Chemical Development World-Wide, Warner Lambert Pharmaceutical Company regarding medicinals prescribed for diabetics. He passed away on October 22, 2012 due to a complication of diabetes mellitus, type 2. He will be missed.

No acknowledgement is complete without mentioning the team of experts who turned the text, figures, and other supplementary materials into a book. Anita Alekhwan, Senior Acquisitions Editor, who oversaw the entire operation and provided me with very wise suggestions, her assistant Cecilia Tsai, Editorial Assistant, Kellsee Chu, Senior Production Editor who coordinated the production phase, Haseen Khan, Project Manager of Laserwords who did the editing, and Dean Gonzalez, Illustration Manager who took my crude line drawings and put them into publishable form. To all of the above my genuine thanks for without you there would be no book.

CHAPTER 1

DIABETES MELLITUS: A PANDEMIC IN THE MAKING

It is a capital mistake to theorize before one has data. Insensibly one begins to twist facts to suit theories, instead of theories to suit facts.

Sir Arthur Conan Doyle, British mystery author & physician (1859–1930)

On December 20, 2006, the General Assembly of the United Nations passed resolution 61/225, the United Nations World Diabetes Day Resolution, designating November 14 as World Diabetes Day. On October 29, 2010, the President of the United States, Barack Obama, declared November 2010 as National Diabetes Month in the United States.¹

Diabetes mellitus² is an array of diseases that have a common symptom—abnormally high blood glucose levels. Diabetes mellitus is a noncommunicable disease. It is not transmitted from person to person by viruses or bacteria as is HIV or cholera. Diabetes mellitus is a chronic, costly, and often debilitating disease. This will be our working definition of diabetes mellitus until later in the book where we shall learn more specifics about the disease. The President, in his Proclamation, uses the terms type 1 and type 2 diabetes. By the end of Chapter 6,

¹See Appendix A for texts of the UN Resolution and President Obama's Proclamation, respectively.

²Diabetes mellitus should not be confused with diabetes insipidus, which is caused by vasopressin deficiency. When the term *diabetes* alone is used in this book it will always refer to diabetes mellitus.

you will fully understand both these terms.³ In this chapter we will learn about the extent of the diabetes problem both in the United States and globally. Later in this chapter we will learn of a related pandemic in the making—obesity and overweight. Finally, we will describe the connections between the diabetes and obesity/overweight pandemics.

DIABETES PREVALENCE⁴ AND COST IN THE UNITED STATES

A Dire Prediction Based on Alarming Data

The Centers for Disease Control and Prevention (CDC) estimated that as of 2008 there were as many as 18.1 million Americans who had been diagnosed with diabetes (8 in 100 Americans). This number is presumed low because it is estimated that 6.0 million cases remain undetected. Thus, 10 in 100 adult Americans actually had the disease in 2008 (1). Between 1980 and 2008, the number of diagnosed diabetic Americans has nearly tripled.

An analysis of this data according to age, gender, and race is revealing. All of the following data derived from the CDC is for civilian, noninstitutionalized individuals with diagnosed diabetes.

Figure 1.1 shows the age-adjusted percentage of diagnosed cases of diabetes by sex. You may notice that percentages were similar for males and females until 1999, at which time the percentage for males with diabetes began to increase at a greater rate than for females.




Figure 1.1 Age-adjusted percentage of civilian, noninstitutionalized persons with diagnosed diabetes by sex for selected years. (See insert for color representation of the figure.)

³Type 1 diabetes refers to hyperglycemia (high blood glucose levels) due to insufficient insulin secretion caused by destruction of pancreatic β -islet cells by an autoimmune response and type 2 refers to hyperglycemia due to insulin resistance (relative insulin deficiency). Type 1 diabetics exhibit blood insulin levels that are low or nonexistent and type 2 diabetics have levels that are high.

⁴Prevalence relates to the number of individuals who have diabetes at the time of the study. Incidence refers to the frequency of occurrence and is associated with a defined period of time.